These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1172 related articles for article (PubMed ID: 18161752)

  • 1. TNF-mediated inflammatory disease.
    Bradley JR
    J Pathol; 2008 Jan; 214(2):149-60. PubMed ID: 18161752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
    Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
    J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms for modulating TNF alpha in immune and inflammatory disease.
    Baugh JA; Bucala R
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):635-50. PubMed ID: 12825458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor in infectious disease.
    Waters JP; Pober JS; Bradley JR
    J Pathol; 2013 Jun; 230(2):132-47. PubMed ID: 23460469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor inhibitors in ankylosing spondylitis.
    Reed MR; Taylor AL
    Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor and anti-tumor necrosis factor therapies.
    Keystone EC; Ware CF
    J Rheumatol Suppl; 2010 May; 85():27-39. PubMed ID: 20436163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular mechanisms of TNF function in models of inflammation and autoimmunity.
    Apostolaki M; Armaka M; Victoratos P; Kollias G
    Curr Dir Autoimmun; 2010; 11():1-26. PubMed ID: 20173385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF and TNFR biology in health and disease.
    McDermott MF
    Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):619-35. PubMed ID: 11502070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways.
    Montecucco F; Steffens S; Burger F; Da Costa A; Bianchi G; Bertolotto M; Mach F; Dallegri F; Ottonello L
    Cell Signal; 2008 Mar; 20(3):557-68. PubMed ID: 18164590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What does tumour necrosis factor excess do to the immune system long term?
    Clark J; Vagenas P; Panesar M; Cope AP
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv70-6. PubMed ID: 16239393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF antibodies: lessons from the past, roadmap for the future.
    Shealy DJ; Visvanathan S
    Handb Exp Pharmacol; 2008; (181):101-29. PubMed ID: 18071943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between TNF and glucocorticoid receptor signaling pathways.
    Van Bogaert T; De Bosscher K; Libert C
    Cytokine Growth Factor Rev; 2010 Aug; 21(4):275-86. PubMed ID: 20456998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1.
    Van Hauwermeiren F; Vandenbroucke RE; Libert C
    Cytokine Growth Factor Rev; 2011; 22(5-6):311-9. PubMed ID: 21962830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TNF: antitumoral agent at the border lines of immunity and inflammation].
    Branellec D; Chouaib S
    Pathol Biol (Paris); 1991 Mar; 39(3):230-9. PubMed ID: 1646993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signalling pathways of the TNF superfamily: a double-edged sword.
    Aggarwal BB
    Nat Rev Immunol; 2003 Sep; 3(9):745-56. PubMed ID: 12949498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept].
    Müller-Ladner U; Alten R; Heiligenhaus A; Kekow J; Koletzko S; Mrowietz U; Ochsenkühn T; Radke M; Reich K; Rudwaleit M; Schreiber S
    Dtsch Med Wochenschr; 2009 Oct; 134(42):2132-6. PubMed ID: 19809965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional relevance of soluble TNF-alpha, transmembrane TNF-alpha and TNF-signal transduction in gastrointestinal diseases with special reference to inflammatory bowel diseases.
    Holtmann MH; Schütz M; Galle PR; Neurath MF
    Z Gastroenterol; 2002 Aug; 40(8):587-600. PubMed ID: 12297983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and nature of infectious disease in patients treated with anti-TNF agents.
    Raychaudhuri SP; Nguyen CT; Raychaudhuri SK; Gershwin ME
    Autoimmun Rev; 2009 Dec; 9(2):67-81. PubMed ID: 19716440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders.
    Holtmann MH; Schuchmann M; Zeller G; Galle PR; Neurath MF
    Arch Immunol Ther Exp (Warsz); 2002; 50(4):279-88. PubMed ID: 12371624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.